These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28450700)

  • 1. Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy.
    Van Woensel M; Mathivet T; Wauthoz N; Rosière R; Garg AD; Agostinis P; Mathieu V; Kiss R; Lefranc F; Boon L; Belmans J; Van Gool SW; Gerhardt H; Amighi K; De Vleeschouwer S
    Sci Rep; 2017 Apr; 7(1):1217. PubMed ID: 28450700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration.
    Van Woensel M; Wauthoz N; Rosière R; Mathieu V; Kiss R; Lefranc F; Steelant B; Dilissen E; Van Gool SW; Mathivet T; Gerhardt H; Amighi K; De Vleeschouwer S
    J Control Release; 2016 Apr; 227():71-81. PubMed ID: 26902800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.
    Danhier F; Messaoudi K; Lemaire L; Benoit JP; Lagarce F
    Int J Pharm; 2015 Mar; 481(1-2):154-61. PubMed ID: 25644286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T7 peptide-decorated exosome-based nanocarrier system for delivery of Galectin-9 siRNA to stimulate macrophage repolarization in glioblastoma.
    Li C; Guan N; Liu F
    J Neurooncol; 2023 Mar; 162(1):93-108. PubMed ID: 36854924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme.
    Kadiyala P; Li D; Nuñez FM; Altshuler D; Doherty R; Kuai R; Yu M; Kamran N; Edwards M; Moon JJ; Lowenstein PR; Castro MG; Schwendeman A
    ACS Nano; 2019 Feb; 13(2):1365-1384. PubMed ID: 30721028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses.
    Le Mercier M; Mathieu V; Haibe-Kains B; Bontempi G; Mijatovic T; Decaestecker C; Kiss R; Lefranc F
    J Neuropathol Exp Neurol; 2008 May; 67(5):456-69. PubMed ID: 18431251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
    Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S
    Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
    Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
    PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving cancer immunotherapy in prostate cancer by modulating T cell function through targeting the galectin-1.
    Wang HC; Xia R; Chang WH; Hsu SW; Wu CT; Chen CH; Shih TC
    Front Immunol; 2024; 15():1372956. PubMed ID: 38953033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous Galectin-1 in T Lymphocytes Regulates Anti-prostate Cancer Immunity.
    Corapi E; Carrizo G; Compagno D; Laderach D
    Front Immunol; 2018; 9():2190. PubMed ID: 30319642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simple self-assembly nanomicelle based on brain tumor-targeting peptide-mediated siRNA delivery for glioma immunotherapy via intranasal administration.
    Tang L; Zhang R; Wang Y; Zhang X; Yang Y; Zhao B; Yang L
    Acta Biomater; 2023 Jan; 155():521-537. PubMed ID: 36384220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Trojan-Horse-Like Biomimetic Nano-NK to Elicit an Immunostimulatory Tumor Microenvironment for Enhanced GBM Chemo-Immunotherapy.
    Zhang L; Zhang Y; Wang X; Zhou Y; Qi J; Gu L; Zhao Q; Yu R; Zhou X
    Small; 2023 Nov; 19(44):e2301439. PubMed ID: 37420326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice.
    Jadidi-Niaragh F; Atyabi F; Rastegari A; Kheshtchin N; Arab S; Hassannia H; Ajami M; Mirsanei Z; Habibi S; Masoumi F; Noorbakhsh F; Shokri F; Hadjati J
    J Control Release; 2017 Jan; 246():46-59. PubMed ID: 27993599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasively Deciphering the Immunosuppressive Tumor Microenvironment Using Galectin-1 PET to Inform Immunotherapy Responses.
    Liu N; Yang X; Gao C; Wang J; Zeng Y; Zhang L; Yin Q; Zhang T; Zhou H; Li K; Du J; Zhou S; Zhao X; Zhu H; Yang Z; Liu Z
    J Nucl Med; 2024 May; 65(5):728-734. PubMed ID: 38514084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunostimulatory silica nanoparticle boosts innate immunity in brain tumors.
    Bielecki PA; Lorkowski ME; Becicka WM; Atukorale PU; Moon TJ; Zhang Y; Wiese M; Covarrubias G; Ravichandran S; Karathanasis E
    Nanoscale Horiz; 2021 Feb; 6(2):156-167. PubMed ID: 33400743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KLF12 overcomes anti-PD-1 resistance by reducing galectin-1 in cancer cells.
    Zheng Y; Zhang H; Xiao C; Deng Z; Fan T; Zheng B; Li C; He J
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergy between glutamate modulation and anti-programmed cell death protein 1 immunotherapy for glioblastoma.
    Medikonda R; Choi J; Pant A; Saleh L; Routkevitch D; Tong L; Belcaid Z; Kim YH; Jackson CM; Jackson C; Mathios D; Xia Y; Shah PP; Patel K; Kim T; Srivastava S; Huq S; Ehresman J; Pennington Z; Tyler B; Brem H; Lim M
    J Neurosurg; 2022 Feb; 136(2):379-388. PubMed ID: 34388730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker.
    Martínez-Bosch N; Vilariño N; Alameda F; Mojal S; Arumí-Uria M; Carrato C; Aldecoa I; Ribalta T; Vidal N; Bellosillo B; Menéndez S; Del Barco S; Gallego O; Pineda E; López-Martos R; Hernández A; Mesia C; Esteve-Codina A; de la Iglesia N; Balañá C; Martínez-García M; Navarro P
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.